SCHEMBL5680

SCHEMBL5680

CCc1ccc(N2CC[C@]3(CC[C@@](O)(COc4ccccc4)CC3)C2)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 14/20 0.43
CYP1A2 P05177 8/20 0.43
CYP2C19 P33261 8/20 0.43
USP2 O75604 7/20 0.43
TSHR P16473 7/20 0.43
CYP2C9 P11712 6/20 0.43
ALDH1A1 P00352 5/20 0.43
HSD17B10 Q99714 5/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPK1 P28482 4/20 0.42
HIF1A Q16665 3/20 0.41
ALOX15 P16050 2/20 0.41
MAPT P10636 1/20 0.41
CYP2D6 P10635 2/20 0.40
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5655 0.84 CYP3A4 (0.40) CYP3A4CYP1A2CYP2C19USP2TSHR
SCHEMBL5667 0.83 CYP3A4 (0.37) CYP3A4CYP1A2CYP2C19USP2TSHR
SCHEMBL5834 0.81 S1PR1 (0.37) CYP3A4CYP1A2CYP2C19USP2TSHR
SCHEMBL10488 0.76 LIPE (0.54)
SCHEMBL10489 0.76 LIPE (0.54)
SCHEMBL12702112 0.76 LIPE (0.54)
SCHEMBL28914522 0.72 ALDH1A1 (0.45) CYP2C19CYP2C9ALDH1A1MEN1KMT2A
SCHEMBL5287 0.72 CHRM4 (0.44)
SCHEMBL12058 0.71 LIPE (0.42) CYP3A4CYP1A2CYP2C19USP2CYP2C9
SCHEMBL4962 0.70 RYR2 (0.41) CYP3A4CYP1A2CYP2C19USP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488493-A1 SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES F. Hoffmann-La Roche AG (CH) 2012-08-22 EP claimed
WO-2011045292-A1 SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2011-04-21 WO claimed